Comparison between Cy then G-CSF and IVE Plus G-CSF in Haematological Malignancies

Aim:
To retrospectively compare the PBPC yields of harvests after IVE with those of standard Cy/G-CSF priming.

Conclusions:
Priming with IVE yields higher PBPC numbers than cyclophosphamide, patients requiring fewer pheresis, therefore reducing the cost.

Official Title

A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies.

Conditions

Study Type

A retrospective study of two mobilization regimens.

Study Design

Patients: 29 multiple myeloma (MM), 16 non-Hodgkin lymphoma (NHL), 4 Hodgkin’s Disease (HD) were harvested after priming with either IVE or Cy/G-CSF.Treatment:IVE + G-CSFifosfamide 3 g/m2 etoposide 200 mg/m2 on days 1 to 3epirubicin 50 mg/m2 on day 1G-CSF 300 microg/day from day 8.Cyclophosphamide + G-CSFCyclophosphamide priming consists on Cy 3 g/m2 on day 1 G-CSF 300 microg/day from day 5.

Further Details

Results:All patients receiving IVE achieved the required cell dose in a maximum of 2 pheresis (40% in one, 60% in two). Both the final and the first pheresis yields are significantly superior in cases mobilized after IVE, whilst no difference was found in the second day of harvest.Click here to see results table.

Study Start

Eligibility & Criteria

Indication:Multiple myeloma, Non Hodgkin’s and Hodgkin’s Lymphoma

Total Enrolment

Contact Details

Abstract 5484 ASH 2005Miguel Ortin et al.Ann Hunter Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom